Applicability of human osteoarthritic chondrocytes for in vitro efficacy testing of anti-TNFα drugs. (January 2017)

• Record Type: Journal Article
• Authors: Žigon-Branc, Sara; Jeras, Matjaž; Blejec, Andrej; Barlič, Ariana
• Is Part Of: Biologicals. Volume 45(2017:Jan.)
• Page Start: 96
• Page End: 101
• Publication Date: 2017-01
• Subjects: Human osteoarthritic chondrocytes (OACs) -- TNF-α -- Gene expression -- In vitro drug testing; Biological products -- Standards -- Periodicals; Biological Products -- Periodicals; Biological Products -- standards -- Periodicals; Produits biologiques -- Normes -- Périodiques; Biological products -- Standards; Periodicals; 615.37
• DOI: 10.1016/j.biologicals.2016.09.013
• Languages: English
• ISSNs: 1045-1056

Abstract

Abstract: In vitro cell-based models are important tools for assessing efficacies of new leads in early phases of drug development. Human osteoarthritic chondrocytes (OACs), obtained from biomedical waste material, represent a valuable, relatively accessible cellular source that could be used for this purpose. By employing reverse transcription-polymerase chain reaction (qRT-PCR) we compared gene expression profiles of key anabolic, catabolic and inflammatory genes of freshly isolated vs. monolayer cultured OACs (passages P0-P2) and non-stimulated vs. tumor necrosis factor alpha (TNF-α) stimulated P2 OACs. After expansion of OACs in monolayer cultures, the expression of almost all analyzed genes significantly decreased. The subsequent addition of TNF-α to OACs at P2 significantly increased expressions of all catabolic and inflammatory genes, leaving the anabolic profile almost unchanged. TNF-α-treated OACs were later utilized for efficacy testing of anti-TNF-α drugs infliximab and etanercept and both significantly reduced the expressions of all catabolic and inflammatory genes tested.